Innovate Biopharmaceuticals to Discuss Fourth Quarter and Full Year 2018 Financial Results and to Provide Corporate and Opera...
March 18 2019 - 7:30PM
Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a
clinical stage biotechnology company focused on developing novel
autoimmune and inflammation therapeutics, announced that it filed
its 2018 Annual Report on Form 10-K today. Innovate plans to host
an earnings conference call Tuesday morning at 8:00 am ET along
with issuing an earning press release before the market opens. The
corporate and operational progress updates previously planned will
now occur during the March 19, 2019, conference call.
Please visit the Investor section of Innovate’s website for
further details on accessing the webcast.
Event: |
Webcast to report
financial results for the fourth quarter and full year ended
December 31, 2018, and to provide corporate and operational
progress updates |
Date: |
Tuesday, March 19,
2019 |
Time: |
8:00 am ET |
A live and archived audio webcast of the conference call will be
available on the Events and Presentations page of Innovate’s
corporate website at www.innovatebiopharma.com.
About Innovate Biopharmaceuticals, Inc. (Nasdaq:
INNT): Innovate is a clinical stage biotechnology company
focused on developing novel therapeutics for autoimmune and
inflammatory diseases. Innovate’s lead drug candidate, larazotide
acetate, has a mechanism of action that renormalizes the
dysfunctional intestinal barrier by decreasing intestinal
permeability and reducing antigen trafficking, such as gliadin
fragments in celiac disease, and bacterial toxins and immunogenic
antigens in nonalcoholic steatohepatitis (NASH). In several
diseases, including celiac disease, NASH, Crohn’s disease,
ulcerative colitis, irritable bowel syndrome (IBS), type 1 diabetes
mellitus (T1DM), chronic kidney disease (CKD), the intestinal
barrier is dysfunctional with increased permeability.
Forward Looking Statements This press release
includes forward-looking statements including, but not limited to,
statements related to the development of drug candidates, our
operations and business strategy, our expected financial results,
and corporate updates. The forward-looking statements contained in
this press release are based on management’s current expectations
and are subject to substantial risks, uncertainty and changes in
circumstances. Actual results may differ materially from those
expressed by these expectations due to risks and uncertainties,
including, among others, those related to our ability to obtain
additional capital on favorable terms to us, or at all, including,
without limitation, to fund our current and future preclinical
studies and clinical trials and the success, timing and cost of our
drug development program and our ongoing or future preclinical
studies and clinical trials, including, without limitation, the
possibility of unfavorable new clinical and preclinical data and
additional analyses of existing data, as well as the risks that
prior clinical and preclinical results may not be replicated. These
risks and uncertainties include, but may not be limited to, those
described in our Annual Report on Form 10-K filed with
the SEC on March 18, 2019, and in any subsequent
filings with the SEC. Forward-looking statements speak only as
of the date of this press release, and we undertake no obligation
to review or update any forward-looking statement except as may be
required by applicable law.
SOURCE: Innovate Biopharmaceuticals, Inc.
Contact: Jennifer K. Zimmons, Ph.D. Investor
Relations Tel: +1-917-214-3514 Email:
jzimmons@innovatebiopharma.com www.innovatebiopharma.com
Innovate Biopharmaceutic... (NASDAQ:INNT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Innovate Biopharmaceutic... (NASDAQ:INNT)
Historical Stock Chart
From Sep 2023 to Sep 2024